In value terms, private equity deal activity increased by 111% in Q2 2023 compared with the previous quarter’s total of $8.2bn and rose by 287% as compared to Q2 2022. Related deal volume increased by 33% in Q2 2023 versus the previous quarter and was 70% higher than in Q2 2022.
Notably, foreign direct investments (fdi)-related deals accounted for a 41% share of the global pharmaceutical industry’s private equity deal activity in Q2 2023, up 52% over the previous quarter.
The top-ranked financial advisors supporting these private equity deals in Q2 2023 were Cantor Fitzgerald; Moelis & Co; UBS Group with 4, 4, 4 deals respectively.
The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Kirkland & Ellis; Baker & McKenzie; Goodwin Procter with 7, 5, 5 deals respectively.
For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
#Private #equity #deal #activity #pharmaceutical #industry #increased